Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Johnson & Johnson (JNJ) Faces A Fresh Valuation Test On DePuy Sale Talk
18.09.2026 09:15
A potential sale of DePuy Synthes for about US$20b has put Johnson & Johnson (JNJ) back in focus for investors watching how management reshapes its MedTech footprint and capital allocation priorities. The share price of Johnson & Johnson sits at US$270.22 after a 1-day share price return of 1.10% and a 90-day share price return of 18.32%. Recent oncology data and portfolio reshaping moves have contributed to a year-to-date share price return of 30.32% and a 1-year total shareholder return of...
Why This Biotech Stock Just Got a Rare Double Upgrade
16.09.2026 16:24
The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees
16.09.2026 15:36
Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year income plan.
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
16.09.2026 15:31
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
16.09.2026 14:31
Recently published Sjogren's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Sjogren's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Is AbbVie the Best Dividend King to Buy in September?
16.09.2026 14:20
It is certainly a good Dividend King to buy in September.
Tempo Therapeutics Closes Oversubscribed $14.5 Million Financing to Advance MAP(TM) Regenerative Technology
16.09.2026 11:02
Financing follows FDA De Novo submission and publication of positive first-in-human clinical resultsCompany strengthens leadership and Board as it advances surgical reconstruction toward commercialization and evaluates opportunities in regenerative aestheticsSAN DIEGO, CA / ACCESS Newswire / September 16, 2026 / Tempo Therapeutics, Inc. ("Tempo"), a clinical-stage regenerative medicine company pioneering synthetic biomaterials designed to promote the formation of healthy, functional tissue, toda
J&J sells Laminar LAA closure assets it bought 3 years ago
16.09.2026 10:58
The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.
Johnson & Johnson (JNJ) Reports Stronger Survival Data In EGFR Mutated Lung Cancer
16.09.2026 07:12
Johnson & Johnson (NYSE:JNJ) reported new clinical trial results for RYBREVANT-based regimens in EGFR-mutated NSCLC at a major oncology conference. The Phase 2b COPERNICUS study showed RYBREVANT plus LAZCLUZE for newly diagnosed patients with EGFR-mutated NSCLC had improved tolerability and fewer treatment-related adverse events. Final data from the Phase 3 PAPILLON trial found first-line RYBREVANT plus chemotherapy produced the longest reported median overall survival in EGFR exon 20...
3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives
15.09.2026 10:01
Retirees don’t need the highest yield on the board. They need the check to keep arriving, and to keep growing, through every recession, rate cycle, and regime change. Three Dividend Kings fit that brief: Coca-Cola, Johnson & Johnson, and PepsiCo. Each has raised its payout for decades without a cut, and one benchmark says it […]
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
15.09.2026 04:00
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
Reported Earlier, J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Rash, Administration-Related Reaction, Venous Thromboembolism Rates Than Intravenous MARIPOSA Regimen
15.09.2026 03:30
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxisFewer than 1% of patients discontinued treatment due to treatment-related events at one
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
15.09.2026 03:00
Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib), with less frequent dosing and prophylactic strategies, can improve the treatment experience for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations. Early results show consistently low rates across key treatme
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
14.09.2026 01:45
Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutations. Patients treated with the combination achieved a median OS of nearly three years (34.3 mon
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
14.09.2026 01:45
Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutations. Patients treated with the combination achieved a median OS of nearly three years (34.3 mon
C3.ai (AI) Just Posted Its Most Promising Quarter In Years
13.09.2026 10:24
On September 2, C3.ai (NYSE:AI) reported its first quarter of fiscal 2027, and the numbers finally matched the promises. Total revenue reached $52.4 million, subscription revenue made up 94% of that at $49.2 million, and total bookings jumped 73% quarter over quarter. Chief Executive Officer Tom Siebel, three months back in the role, said the […]
Johnson & Johnson (NYSE:JNJ): A Dividend Quality Pick for Income Investors
12.09.2026 11:40
JNJ fits ChartMill's Best Dividend Stocks screen for income investors: 3.12% yield, durable dividend growth, strong profitability, and solid health.
Jaguar LAA, Inc. Announces Acquisition of Assets Related to the Laminar Program
11.09.2026 19:37
Jaguar LAA, Inc. ("Jaguar"), a privately held medical device company, today announced the acquisition of assets related to the Laminar program, focused on addressing the left atrial appendage ("LAA") in patients with non-valvular atrial fibrillation ("AFib"), from Johnson & Johnson.
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
10.09.2026 17:05
If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
10.09.2026 11:45
LIMERICK, Ireland, September 10, 2026--Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies.